If you or a loved one have been diagnosed with stage IV non-small cell lung cancer (NSCLC), Biomarker Assist may be able to help you save on the cost of comprehensive biomarker testing, including KRAS G12C.*
Since approximately 1 in 8† people living with NSCLC‡ have the KRAS G12C biomarker,1 testing for it is important so your doctor can tailor your treatment plan to your needs.2
*Program limitations apply; please see terms and conditions including limits on individual program coverages.
†1/8 = 12.5% which is approximately equal to 12.4% prevalence of non-squamous NSCLC
‡Based on non-squamous patient population.
After your doctor decides which test is right for you, two different programs can reduce the cost of testing. Read more about these programs below:
Biomarker Assist:
NGS Affordability Program
The following list of criteria helps to determine if you qualify for the program. In order to be eligible, you must:
Please note, the program does not cover any other costs, including, but not limited to, office visit fees and biopsy fees. There is also a one-time maximum benefit of $1000.
See NGS Affordability enrollment form for full eligibility details; other restrictions may apply. Terms and Conditions
Have you received
your
EOB?
Click
here to
enroll
You may download, complete, and send the form and required documents to Biomarker Assist:
Click here to download the enrollment form
Submit by mail
Biomarker Assist
NGS Affordability Program
PO Box 2355
Morristown, NJ 07962
Or submit by fax
1-866-671-9373
Have questions call:
(866) AMG-ASST
(1-866-264-2778)
Biomarker Assist:
KRAS Single Gene Test Program
If your doctor chooses a Single Gene Test (SGT), there is nothing you need to do. If you are eligible to participate in the program, the doctor’s office will take care of the paperwork, and the cost of the test is covered through the program.† Ask your doctor for more information about the process.
This is a summary; please see full terms and conditions for program requirements and limitations.
†Program limitations apply, please see terms and conditions including limits on individual program coverages. Programs valid for testing performed through December 31, 2023.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 80%-85% of lung cancer cases.3 Your doctor may talk to you about the type and stage of your disease, using numbers that show the level of severity and if it has spread. For example, stage 0 lung cancer is less severe and localized, and stage IV is more severe and has spread. There can be different treatments for lung cancer depending on the type and stage, so knowing the stage can help guide your doctor’s treatment choices.4
A biomarker is a code in your tumor that contains important information which can help your doctor understand what’s causing your tumor to grow and spread. KRAS G12C is a type of biomarker in NSCLC.5
KRAS is a protein we all have in our bodies that works like an on/off switch, telling our cells when to grow and when to stop growing. Sometimes this protein can mutate (change). KRAS G12C is one of these mutations, and it makes the on/off switch get stuck in the “on” position. This causes cells to multiply uncontrollably and grow into tumors.6-8
Laboratories can analyze a tissue sample of your tumor (from a biopsy) or in some cases your blood to test for any biomarkers it may have. Biomarkers can provide information about your type of cancer. There are two kinds of biomarker tests that your doctor can order. Next Generation Sequencing is a test that looks for many different kinds of biomarkers at a time. Single Gene Testing is used by doctors to look for just one biomarker at a time.9 Getting tested will show if you’re among the 1 in 8 people with NSCLC who have the KRAS G12C biomarker.1 With this information in hand, your doctor can tailor your treatment plan.2 Ask your doctor which test may be right for you.
Biomarker Assist is comprised of two programs, the Next Generation Sequencing (NGS) Affordability Program and the KRAS Single Gene Test (SGT) Program. Please refer to subsequent questions for more details on each program. Programs valid for testing performed through December 31, 2023.
The Biomarker Assist NGS Affordability Program may help eligible, commercially insured patients lower out-of-pocket costs for their NGS biomarker test, including deductible, co-insurance, and co-payment. Eligible patients may pay as little as $0 out-of-pocket for their NGS biomarker test, up to the program maximum of $1000.† There is no income requirement for the Biomarker Assist NGS Affordability Program.
This is a summary; please see full terms and conditions for program requirements and limitations.
The Biomarker Assist KRAS Single Gene Test Program is a voucher program to cover the costs of the KRAS Single Gene Test prescribed by your doctor. All you need to do is ask your doctor if this test is right for you.
This is a summary; please see full terms and conditions for program requirements and limitations.
The Biomarker Assist NGS Affordability Program is available for eligible, commercially insured patients with stage IV metastatic non-small cell lung cancer (NSCLC) with NGS biomarker test coverage (this program covers eligible patient's out-of-pocket obligations after insurance coverage).
The Biomarker Assist KRAS Single Gene Test Program is available for any patient with stage IV metastatic non-small cell lung cancer regardless of insurance type or status.
Eligible patients may pay as little as $0 out-of-pocket for the NGS biomarker test, up to the program maximum of $1000.†
If you do not send the EOB form to Biomarker Assist within 180 days of the date of service, you will not be eligible for reimbursement. Test must be completed by December 31, 2023 and last day to submit documentation is June 29, 2024.
If you paid your out-of-pocket to the lab, once the Explanation of Benefits (EOB) and proof of payment are received, and eligibility confirmed, the check if sent by UPS will arrive in 7 business days to the address you provided. If you have not paid your out-of-pocket to the lab, once the EOB are received, and eligibility confirmed, the check if sent by UPS will arrive in 7 business days to the lab.
This is a summary; please see full terms and conditions for program requirements and limitations.
References: 1. Data on file, Amgen; [Analysis of AACR Genie v12]. 2. Gregg JP, et al. Transl Lung Cancer Res. 2019;8(3):286-301. 3. American Cancer Society. About Lung Cancer. Accessed November 19, 2022. https://www.cancer.org/cancer/lung-cancer/about/what-is.html 4. American Cancer Society. Treatment Choices for Non-Small Cell Lung Cancer, by Stage. Accessed November 19, 2022. http://www.cancer.org/cancer/lung-cancer/treating-non-small-cell/by-stage.html 5. NCI, Biomarker Testing for Cancer Treatment. Accessed November 19, 2022. https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment 6. NCI Dictionary of Cancer Terms, KRAS Gene. Accessed November 19, 2022. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/kras-gene 7. Ryan MB, Nat Rev Clin Oncol. 2018;15(11):709-720. doi: 10.1038/s41571-018-0105-0 8. Hong DS, N Engl J Med. 2020; 383:1207-1217. doi:10.1056/NEJMoa1917239 9. Sherwood JL, et al. ESMO Open. 2017;2:e00235.doi:10.1136/esmoopen-2017-000235